Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway inhibition is the standard of care for patients with symptomatic myelofibrosis (MF); however, a significant number of hematologists/oncologists lack knowledge, competence, and confidence about JAK inhibitors (JAKis)…
Patients with triple negative and HR-positive/HER2-negative breast cancer have limited treatment options after the development of endocrine resistance. This dearth of options is particularly acute for Black women and other marginalized patients, and results in treatment…
The treatment paradigm in bladder cancer has fundamentally changed over the past decade, and the evolving, dense clinical trial landscape has given rise to barriers to optimizing patient care. This Community Connections Grand Rounds series will…
The treatment paradigm in bladder cancer has fundamentally changed over the past decade, and the evolving, dense clinical trial landscape has given rise to barriers to optimizing patient care. This Community Connections Grand Rounds series will…
Patients with triple negative and HR-positive/HER2-negative breast cancer have limited treatment options after the development of endocrine resistance. This dearth of options is particularly acute for Black women and other marginalized patients, and results in treatment…
The reduced incidence of cervical cancer over the past few decades was primarily due to robust screening guidelines and vaccinations. However, despite the proliferation of screening programs, the diagnosis of cervical cancer is associated with inefficiencies…
Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway inhibition is the standard of care for patients with symptomatic myelofibrosis (MF); however, a significant number of hematologists/oncologists lack knowledge, competence, and confidence about JAK inhibitors (JAKis)…
The treatment paradigm in bladder cancer has fundamentally changed over the past decade, and the evolving, dense clinical trial landscape has given rise to barriers to optimizing patient care. This webcast will focus on emerging trial…
Patients with HR-positive/HER2-negative metastatic breast cancer (mBC) who receive antibody-drug conjugates (ADCs) have a unique spectrum of adverse events (AEs) that can lower quality of life (QoL). Patients and caregivers rely on health care providers for…
The rapid evolution of the HR-positive/HER2-negative treatment landscape has led to multiple revisions of clinical practice guidelines. Health care practitioners are challenged to consider the most current data while fine-tuning therapy selections, but also to incorporate…